HERCULES, Calif. -- Bio-Rad Laboratories, Inc., a multinational manufacturer and distributor of life science research products and clinical diagnostics, announced today that the Food and Drug Administration (FDA) has approved a National Institute of Health (NIH)-sponsored IDE (Investigational Device Exemption) for its Platelia Aspergillus EIA test kit for use in a National Heart, Lung and Blood Institute-sponsored study of bone marrow transplant recipients. This population is typically prone to invasive aspergillosis, a serious fungal infection causing high mortality rates in immunocompromised patients. The FDA IDE approval will allow for use of the test for this important study.
Invasive aspergillosis is a respiratory fungal infection that is very difficult to diagnose. Traditional methods of detection like histopathological examination, biopsy and, or radiological examinations not only require invasive surgical procedures, but can produce results that are inconclusive, often leading to inappropriate treatment and death. The Bio-Rad Aspergillus test, however, is a monoclonal antibody based microplate assay, which is a test method used in a variety of clinical applications such as HIV, infectious disease and food pathogen testing.
"We are very excited to have the opportunity to study patients with Bio-Rad's Aspergillus test in this large multi-center clinical trial," said principal investigator Dr. John R. Wingard, professor of medicine and director of the Blood and Marrow Transplant Program at the University of Florida Shands Cancer Center.
"Use of the Bio-Rad test kit will simplify this study and maximize the accuracy of researchers' results so they can focus on the most important task of finding effective drug treatments for this fatal infection," said John Goetz, vice president of Bio-Rad's Clinical Diagnostics Group. "We are hopeful that this research will lead to improved medical treatment and that our test kit will be made available for widespread use in the U.S. in the very near future"
Bio-Rad Laboratories, Inc.is a multinational manufacturer and distributor of life science research products and clinical diagnostics.
Source: Bio-Rad Laboratories, Inc.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.